Join the Myelofibrosis group to help and get support from people like you.
Myelofibrosis News
Related terms: Idiopathic myelofibrosis, Myeloid metaplasia, Agnogenic myeloid metaplasia, Primary myelofibrosis, Secondary myelofibrosis, MF
AI Improves Risk Prediction in Patients With Myelofibrosis Undergoing Allo-HCT
FRIDAY, April 4, 2025 – For patients with myelofibrosis undergoing allogeneic hematopoietic cell transplantation (allo-HCT), machine learning (ML) enhances risk stratification, according to a study...
Pelabresib Plus Ruxolitinib Improves Underlying Myelofibrosis
THURSDAY, March 27, 2025 – Pelabresib, a bromodomain and extraterminal domain inhibitor, plus ruxolitinib (a Janus kinase [JAK] inhibitor) improves signs of underlying myelofibrosis in JAK...
FDA Approves Ojjaara (momelotinib) for Myelofibrosis Patients with Anemia
Approval is for use in myelofibrosis patients with anemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop anemia over the course of the disease,...
FDA Approves Vonjo (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
SEATTLE, Feb. 28, 2022 /PRNewswire/ – CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved Vonjo (pacritinib) for the treatment of adults with...
FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis
SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ: CELG) today announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients...